🧾 What This Document Is

This is a quarterly earnings report (an 8-K filing) for Simulations Plus, covering the second quarter of their 2026 fiscal year (which ended February 28, 2026). Companies file these to update investors on their recent financial performance and business health. Think of it as a "report card" for the past three months.

🏢 What The Company Does

👉 In simple terms, Simulations Plus creates computer models and AI tools that help pharmaceutical companies discover and develop new drugs faster and more efficiently. Instead of just trial-and-error in a lab, their software lets scientists simulate how a drug might work in the human body before spending millions on physical tests. They operate in the fast-growing "biopharma tech" industry, helping big drug companies save time and money.

💰 Financial Highlights (The Quarter)

The company had a strong quarter, with profits growing faster than sales.

• Total Revenue: Grew 8% to $24.3 million.
  • Software Sales (60% of revenue): Up 9% to $14.6 million. This is their high-margin, core product.
  • Services (40% of revenue): Up 8% to $9.7 million. This includes consulting and analysis work.
• Profitability surged:
  • Gross Profit Margin: Jumped to 66% (up from 59%), meaning they kept more of each dollar of sales after direct costs.
  • Net Income: Rose to $4.5 million, up from $3.1 million.
  • Earnings Per Share (EPS): $0.22, up from $0.15.

Why it matters: Revenue growth is solid, but the big story is the massive jump in profit margins. This suggests the company is becoming much more efficient or its newer products/services are more profitable.

📈 Six-Month Trend & The "Backlog" Signal

Looking at the first half of the fiscal year tells a more nuanced story:

• Total revenue grew a more modest 3% to $42.7 million.
• Software sales actually dipped 3%, while Services grew 12%.
• Key Metric: The company highlighted that its backlog (future contracted work) grew by 18%. This is a forward-looking indicator that demand is strong, even if some software sales shifted timing.

Why it matters: While the half-year software sales are slightly down, the exploding backlog suggests a wave of future revenue is locked in. The company is also seeing success in signing up new clients ("new logos") and getting existing clients to buy more.

🔮 Updated Guidance & The Tax Impact

The company lowered its full-year profit forecast, but not because of business problems.

• The Change: Adjusted EPS guidance was lowered from a range of $1.03-$1.10 to $0.75-$0.85.
• The Reason: They now expect their effective tax rate to be 23-25%, much higher than the previously expected 12-14%.
• Business Outlook Unchanged: Revenue ($79M-$82M) and Adjusted EBITDA margin (26-30%) forecasts remain the same.

Why it matters: This is crucial. The operational business is performing as expected, but a external, one-time tax change is reducing the final profit that goes to shareholders. It's like your pay raise being offset by a new tax—you earned more, but take home less.

📦 Financial Position (Balance Sheet Snapshot)

• Cash & Investments: A solid $25.7 million in cash plus $16.1 million in short-term investments provides a strong cushion.
• Debt: The company carries very little debt (only lease obligations), which is a sign of financial health.
• Assets: The largest asset is Goodwill ($43.7 million) on the books, from past acquisitions. This represents the intangible value of the companies they bought.

Why it matters: The balance sheet is strong and flexible. Low debt means they aren't burdened by interest payments, and they have cash to invest in growth or weather a downturn.

⚖️ Big Picture: Strengths & Risks

👍 Strengths:

• Growing Demand: Management says the market is favorable, with better drug funding and supportive regulatory guidance.
• Profit Machine: High and improving margins show strong pricing power and operational efficiency.
• Recurring Revenue: Their software model likely has high renewal rates, creating predictable income.
• Strong Backlog: The 18% increase in backlog provides visibility into future quarters.

⚠️ Risks:

• Tax Rate Headwind: The higher-than-expected tax rate will directly reduce shareholder profits this year.
• Customer Concentration: Like many in this space, they may rely on a number of large biopharma clients.
• Integration & Competition: They need to continue integrating past acquisitions and stay ahead of other AI-driven drug development tools.

🧠 The Analogy

Simulations Plus is like a high-end architectural firm for the drug world. Pharmaceutical companies are the construction clients. Instead of building expensive, risky physical prototypes (actual drug trials), Simulations Plus provides incredibly detailed blueprints and computer simulations (their models and AI) to show what will work. They charge high fees for this expertise (strong margins), and the construction boom (favorable pharma funding) means more clients need their services, leading to a large order book (backlog).

🧩 Final Takeaway

The core business is healthy and growing, with strong margins and a swelling backlog. However, investors' final take-home profit for the year will be significantly lower than initially expected solely due to a higher tax rate, not because of any operational weakness. The story is one of solid performance meeting an unexpected tax bill.